A Study of Azacitidine and Venetoclax in People With Acute Myeloid Leukemia (AML)

This study is testing a combination of azacitidine (a low-intensity chemotherapy) and venetoclax (a targeted drug that helps cancer cells die) as a first-line treatment for adults with newly diagnosed acute myeloid leukemia (AML), a blood cancer, who are not suitable for intensive chemotherapy. **You may be eligible if...** - You are 18 or older with a newly confirmed diagnosis of AML (not the APL subtype) - You are not a candidate for intensive chemotherapy - You have not received prior treatment for AML - You are willing to comply with study visits and procedures **You may NOT be eligible if...** - You have acute promyelocytic leukemia (APL) or relapsed/refractory AML - You have previously been treated with a venetoclax-containing regimen - You have blast crisis of chronic myeloid leukemia - Your bone marrow has 5% or more abnormal blast cells from another condition - You have other serious health conditions that could interfere with treatment Talk to your doctor to see if this trial is right for you.